Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whats the point ? This shows Stanford working along side Paul M. McKeigue {London School of Hygiene and Tropical}who's with Dnap now
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
http://www.humanapress.com/ProductDetail.pasp?txtCatalog=HumanaBooks&txtProductID=1%2D59259%2D71...
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Insulin Resistance
The Metabolic Syndrome X
Reaven, Gerald M. (Stanford University School of Medicine, Stanford, CA)
Laws, Ami (Stanford University School of Medicine, Stanford, CA)
Binding: About eBooks
File size: 3,613 kb
List Price: $130.00
10% Online Discount: - 13.00
You Pay: $117.00
Table of Contents Back to Book Detail
Part I. Genetic and Environmental Factors Affecting Insulin Action. Genetics of Insulin Resistance, Michael P. Stern and Braxton D. Mitchell. Ethnic Variation in Insulin Resistance and Risk of Type 2 Diabetes, Paul M. McKeigue. Fetal Effects on Insulin Resistance and Glucose Tolerance,Paul M. McKeigue. Obesity and Insulin Resistance: Epidemiologic, Metabolic, and Molecular Aspects, Jean-Pierre Després and André Marette. The Role of Body Fat Distribution in Insulin Resistance, Abhimanyu Garg. Physical Activity and Insulin Resistance in Man, Flemming Dela, Kári Mikines, and Henrik Galbo. Insulin Resistance in Smokers and Other Long-Term Users of Nicotine, Björn Eliasson and Ulf Smith. Part II. Pathophysiology of Insulin Resistance. Insulin Resistance and Inhibitors of Insulin Receptor Tyrosine Kinase, Jack F.Youngren, Ira D. Goldfine, Vincenzo Trischitta, and Betty A. Maddux. NMR Studies on the Mechanism of Insulin Resistance, Gianluca Perseghin, Kitt Falk Petersen, and Gerald I. Shulman. Skeletal Muscle Insulin Resistance in Humans: Cellular Mechanisms, Lawrence J. Mandarino. The Role of the Liver in Insulin Action and Resistance, Jerry Radziuk and Susan Pye. The Pathophysiological Consequences of Adipose Tissue Insulin Resistance, Gerald M. Reaven. Insulin Action and Endothelial Function, Alain D. Baron and Michael J. Quon. Part III. Clinical Syndromes Associated with Insulin Resistance. Insulin Resistance and Dyslipidemia: Implications for Coronary Heart Disease Risk, Ami Laws. Insulin Resistance and Blood Pressure, Ele Ferrannini. Microalbuminuria and Insulin Resistance, Jeannie Yip and Roberto Trevisan. PAI-1, Obesity, and Insulin Resistance, Irène Juhan-Vague, Marie-Christine Alessi, and Pierre E. Morange. Insulin Resistance and Cardiovascular Disease, Aaron R. Folsom. Insulin Resistance Effects on Sex Hormones and Ovulation in the Polycystic Ovary Syndrome, John E. Nestler.
Today's wisdom,I hope you all enjoy - A Glass of Milk - One day, a poor boy who was selling goods from door to door to pay his way through school, found he had only one thin dime left, and he was hungry.
He decided he would ask for a meal at the next house. However, he lost his nerve when a lovely young woman opened the door.
Instead of a meal he asked for a drink of water. She thought he looked hungry so brought him a large glass of milk. He drank it slowly, and then asked, How much do I owe you?"
You don't owe me anything," she replied. "Mother has taught us never to accept pay for a kindness."
He said..... "Then I thank you from my heart."
As Howard Kelly left that house, he not only felt stronger physically, but his faith in God and man was strong also. He had been ready to give up and quit.
Many year's later that same young woman became critically ill. The local doctors were baffled. They finally sent her to the big city, where they called in specialists to study her rare disease.
Dr. Howard Kelly was called in for the consultation. When he heard the name of the town she came from, a strange light filled his eyes.
Immediately he rose and went down the hall of the hospital to her room.
Dressed in his doctor's gown he went in to see her. He recognized her at once.
He went back to the consultation room determined to do his best to save her life. From that day he gave special attention to her case.
After a long struggle, the battle was won.
Dr. Kelly requested the business office to pass the final bill to him for approval. He looked at it, then wrote something on the edge and the bill was sent to her room. She feared to open it, for she was sure it would take the rest of her life to pay for it all. Finally she looked, and something caught her attention on the side of the bill. She read these words...
"Paid in full with one glass of milk"
(Signed) Dr. Howard Kelly.
Tears of joy flooded her eyes as her happy heart prayed: "Thank You, God, that Your love has spread broad through human hearts and hands."
There's a saying, which goes something like this: Bread cast on the waters comes back to you. The good deed you do today may benefit you or someone you love at the least expected time. If you never see the deed again at least you will have made the world a better place - And, after all, isn't that what life is all about?
Then we go to the moon
I say 3-D face scanner,Hair color,eye color and ears lobs.This Mo. follow by ABC - CBS - NBC - 20/20 Tom dick and harry
Tony didnt come out with eye color early this year because he wants to have a Bigger package to come out with.
Dnap will make Millions.EOM
Dnap will be Big.EOM
Yes its an idea who's time has come !! The right time in history is well put. Moffitt<--->Mayo<--->University of South Florida<--->seem to be the clinical testing grounds for Dnaprint Genomics. Other big "maybe's" could very well be Stanford University Medical and Duke involved with the clinical testing side of Dnaprint Genomics products.Who's jumped in to help make it happen you can Affmetrix and IBM.I have to say for Dnap to keep such a low profile in all of this "Setting the Gold Standard" HAS to be a understatment. They must have something so Dam BIG it will rock wall street to its knees.To draw in all these big names is a Big sign of something Big about to come.
The H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida is collaborating with IBM and Affymetrix
Wisdom for the day - "It is not the critic who counts, not the man who points out how the strong man stumbled, or where the doer of deeds could have done better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who strives valiantly, who errs and comes short again and again, who knows the great enthusiasms, the great devotions, and spends himself in a worthy cause, who at best knows achievement and who at the worst if he fails at least fails while daring greatly so that his place shall never be with those cold and timid souls who know neither victory nor defeat."
Tony Look into my eye's look deeply into my eyes ~~~You are now under my power you will Merg with Big Pharma, Merg Tony !! Merrrrrrrrrrrggggggggg when I click my mouse you will remember nothing.
Are we working with 2 different Dept. in IBM ? 1} in forensics with Dr.Sturm and 2} at H.Lee Moffit !!! 2 Different Dept. 2 different places with IBM ? Could there be 3 or 4, IBM MUST have both Eye Balls on us.
And who could forget this- -ADMIXMAP will allow DNAPrint to identify new disease and drug response genes 10 times faster and 1,000-times less expensively than others who use existing methods. Dr. Tony Frudakis, CEO, informally announced the introduction of ADMIXMAP to attendees at the invitation-only IBM Life Science Solution Developer Conference in Boca Raton, FL, and proclaimed the Company's intent to partner collaborative services based on the platform to pharma, biotech and academia.
Dr. Sitarama Brahmam Gunturi
Ramabrahmam was born in East Godavari District of Andhra Pradesh, India. He obtained his master’s and Ph.D degrees in Applied Mathematics from Andhra University(1989) and IITM – Chennai (1996) respectively. During the doctoral program, he studied the applications of wavelet based numerical methods to non-linear partial differential equations. During the period 1996 – 2001, he worked in Telecom and data warehousing projects of TCS. He joined DNAPrint Genomics Inc., a Florida based company in 2001 and worked in Bio-informatics. During this period (2001 – 2003), he was instrumental in developing the Ancestry Test kit and in solving the Human Eye Colour Classification problem.
His interests are in developing statistical models for detecting the phenotypic-genotypic associations and classifications.
Reference Link: http://atcweb.atc.tcs.co.in/Bio-info.html
------
IBM's view of the Moffitt collaboration - part of a larger "global" picture of advancing medicine...
Nice to know DNAPrint Genomics fits in here somehow...
IBM launches $250 million global healthcare initiative
New collaborations with Duke University Health System and H. Lee Moffitt Cancer Center & Research Institute aim to transform medicine
Issue Date 19 Feb 2004
Location Somers, NY
IBM today announced a major healthcare initiative to help healthcare providers and payers manage costs, reduce medical errors, and deliver better patient care. The initiative will infuse an estimated $250 million of investments into IBM's healthcare business over the next three years for new hiring of healthcare specialists, solutions development, research and development projects, IBM Business Partner collaborations, and other programs.
Highlights include:
* Groundbreaking collaborations with Duke University Health System and the Moffitt Cancer Center & Research Institute;
* New healthcare solutions designed to support information-based medicine initiatives and bring safer, more efficient approaches to healthcare;
* The formation of the IBM Center for Healthcare Management;
* Creation of the IBM Research Healthcare and Life Sciences Institute; and
* New IBM Clinical Transformation consulting practice and IBM Information Based Medicine business unit.
"The healthcare industry is under tremendous pressure to address patient safety, quality of care and cost issues," said Dr. Caroline Kovac, general manager of IBM Healthcare and Life Sciences. "IBM is deeply committed to developing the on demand solutions and offering the consulting expertise and business insights that can help the healthcare industry transform. Working with IBM Business Partners, we can help bring catalytic change and help the industry deliver on the promise of better patient care."
New Collaborations
Duke University Health System and IBM are collaborating on a unique on demand information management system. Duke On Demand will be used to help speed critical information to researchers and clinicians that can facilitate identification of new, more effective treatments for diseases such as breast cancer and heart disease.
The system is being designed to integrate clinical data, such as patient records and lab tests, with research findings about genes and proteins to help give doctors a more complete "personalized" picture of a patient's medical condition, while protecting patient confidentiality. The solution also can be used to electronically locate and initially screen potential candidates for clinical trials and for physician training.
"Duke and IBM share a vision around prospective medicine," said Dr. Ralph Snyderman, Chancellor for Health Affairs, Duke University Medical Center, and Executive Dean of Duke School of Medicine. "IBM has made a large-scale commitment to cutting-edge technology in the life sciences. By mobilizing our respective resource bases and complementary skills, together we can make a big difference in the delivery of healthcare in the 21st century."
The H. Lee Moffitt Cancer Center & Research Institute and IBM are collaborating on a disease management system designed to help researchers and clinicians screen patients at risk for diseases and identify potential clinical trial participants faster. The new Clinical Research Data Warehouse, part of Moffitt's Total Cancer Care program, will focus initially on lung cancer and will integrate data from more than 30 disparate databases throughout the hospital and research center. Moffitt is located at the University of South Florida and has more than 280 physicians, 600 researchers, and a network of 13 affiliate hospitals throughout Florida.
New Healthcare Offerings and Information Resources
A key focus of IBM's healthcare initiative will be the development of consulting practices, information resources, and customized industry solutions to help transform hospitals and small and medium healthcare providers, accelerate medical research, and optimize processes to help lower healthcare costs. Each new solution or information resource will leverage the healthcare industry insight and consulting methodologies of IBM Business Consulting Services and the deep technology skills and resources of IBM Healthcare and Life Sciences.
Among the practices, information resources, and customized solutions announced today are:
-- Simulation and Modeling Services for the Safer and Leaner Healthcare Provider, leading processes, strategies and methodologies, including optimization modeling and simulation tools, to help hospitals improve resource allocation, utilization and planning. These customized decision-support services measure the performance of both clinical and administrative processes, identify cost parameters, and offer insights into "best practices" from other industries that can help healthcare providers reduce medical errors and improve patient care quality, while reducing costs and streamlining operations.
-- IBM's Aligned Clinical Environment, a solution that helps healthcare providers integrate, analyze and manage complex and disparate clinical, research and administrative data from multiple systems. The Aligned Clinical Environment provides business insights, tools and methodologies for creating an information-on-demand environment that can help improve clinical quality, safety and patient care. For example, the Healthcare Collaborative Network, a consortium of public and private sector organizations, including hospitals and health systems, is using the information technology infrastructure and services from the Aligned Clinical Environment to demonstrate the feasibility and value of a nationwide, real-time surveillance system that can help detect, respond to, and report adverse healthcare and drug events and improve healthcare quality. The system, which is now operational, includes automated reporting of infectious disease outbreaks.
-- IBM Center for Healthcare Management, a resource for information and dialogue on critical issues facing healthcare payers and providers. The new center will sponsor discussion forums on topics ranging from disease surveillance to healthcare collaboration and data management for informed healthcare decisions. It will also support the development of research reports and case studies on innovative industry approaches to improving quality and efficiency.
-- IBM Research Healthcare and Life Sciences Institute, which will work with IBM's eight research labs around the world to drive invention and technology innovation specifically targeting the healthcare, life sciences and the pharmaceutical industries.
-- IBM's Clinical Transformation Practice, which brings together consultants who are also clinicians, including physicians and nurses, and hospital administrators, with business intelligence experts, and leading quality experts to help clients who span a broad spectrum of healthcare areas.
-- IBM's Information Based Medicine Business Unit, formed to bring greater focus to the critical role advanced information technologies play in the emerging field of personalized medicine. Information-based medicine uses information technology to help doctors deliver more personalized healthcare, making available data such as genetic profiles, medical images and other research that can be integrated with clinical information to give a more complete picture of factors that may influence a patient's medical condition.
About IBM Healthcare and Life Sciences
IBM Healthcare and Life Sciences brings together IBM resources, including information technology, deep industry insights, and research expertise, to help clients develop and deliver safer, more affordable and more effective diagnostics, drugs and medical care.
Partial 'Blue Gene' Systems Are Now Two of the Top Ten Most Powerful Supercomputers on Earth
June 21, 2004--For the first time, two IBM Blue Gene/L prototype systems appear on the Top 10 list of supercomputers. The Blue Gene/L prototype represents a radical new design for supercomputing. At 1/20th the physical size of existing machines of comparable power, Blue Gene/L enables dramatic reductions in power consumption, cost and space requirements for businesses requiring immense computing power. For a new architecture to produce so much compute power in such a small package is a stunning achievement, and provides a glimpse of the future of supercomputing.
The number four-ranked Blue Gene/L DD1 Prototype, with a sustained speed of 11.68 teraflops and a peak speed of 16 teraflops, uses more than 8,000 PowerPC processors packed into just four refrigerator-sized racks. This ground breaking system is only 1/16 of its planned final capacity and has skyrocketed to the 4th place from the 73rd spot on the list in November 2003. The eighth-ranked Blue Gene/L DD2 Prototype has a sustained speed of 8.66 teraflops and a peak speed of 11.47 teraflops. The DD2 system is based on the second generation of the Blue Gene/L chips, which are more powerful than those used in the DD1 prototype.
About IBM's Blue Gene Supercomputing Project
Blue Gene is an IBM supercomputing project dedicated to building a new family of supercomputers optimized for bandwidth, scalability and the ability to handle large amounts of data while consuming a fraction of the power and floor space required by today's fastest systems. The full Blue Gene/L machine is being built for the Lawrence Livermore National Laboratory in California, and will have a peak speed of 360 teraflops. When completed in 2005, IBM expects Blue Gene/L to lead the Top500 supercomputer list. A second Blue Gene/L machine is planned for ASTRON, a leading astronomy organization in the Netherlands. IBM and its partners are currently exploring a growing list of applications including hydrodynamics, quantum chemistry, molecular dynamics, climate modeling and financial modeling.
IBM Surges Past HP To Lead in Global Supercomputing
Partial 'Blue Gene' Systems Are Now Two of the Top Ten Most Powerful Supercomputers on Earth - New Era In Supercomputing Arrives
ARMONK, N.Y. -- June 20, 2004 -- An independent study released today named IBM as the world's leading provider of both installed supercomputing systems (with 224 systems) as well as total aggregate supercomputing power (with a record total 407 teraflops, or trillions of calculations per second). According to analysis from the TOP500 List of Supercomputers, IBM is the leader in global supercomputing with 50 percent of the total processing power, which is two and a half times more processing power than its closest rival, runner up Hewlett Packard with 19 percent.
For the first time, two IBM Blue Gene/L prototype systems appear on the Top 10 list of supercomputers. The Blue Gene/L prototype represents a radical new design for supercomputing. At 1/20th the physical size of existing machines of comparable power, Blue Gene/L enables dramatic reductions in power consumption, cost and space requirements for businesses requiring immense computing power. For a new architecture to produce so much compute power in such a small package is a stunning achievement, and provides a glimpse of the future of supercomputing.
The number four-ranked Blue Gene/L DD1 Prototype, with a sustained speed of 11.68 teraflops and a peak speed of 16 teraflops, uses more than 8,000 PowerPC processors packed into just four refrigerator-sized racks. This ground breaking system is only 1/16 of its planned final capacity and has skyrocketed to the 4th place from the 73rd spot on the list in November 2003. The eighth-ranked Blue Gene/L DD2 Prototype has a sustained speed of 8.66 teraflops and a peak speed of 11.47 teraflops. The DD2 system is based on the second generation of the Blue Gene/L chips, which are more powerful than those used in the DD1 prototype.
"By giving our clients access to innovative, affordable and flexible supercomputing power like Blue Gene and the Deep Computing Capacity on Demand Center, we are providing new resources to drive breakthroughs in business, science and industry," said Dave Turek, vice president, Deep Computing, IBM. "Whether we are talking about improving the accuracy of weather forecasts, designing better automobiles or improving disease research, we are seeing the advent of a new supercomputing age."
Other key indicators of IBM supercomputing leadership:
IBM has 224 supercomputer systems installed, most of any vendors (44.8 percent of the list are IBM systems)
IBM has most installed computing power with over 407 Teraflops. (50 percent of the total power on the list belongs to IBM)
IBM has the most supercomputers in the Top10 (3)
IBM has the most supercomputers in the Top20 (10)
IBM has the most supercomputers in the Top100 (68)
IBM has the most Linux clusters on the TOP500 List (150)
The "TOP500 List Supercomputing Sites" is compiled and published by supercomputing experts Jack Dongarra from the University of Tennessee, Erich Strohmaier and Horst Simon of NERSC/Lawrence Berkeley National Laboratory and Hans Meuer of the University of Mannheim (Germany). The entire list can be viewed at http://www.top500.org.
About IBM's Blue Gene Supercomputer Project
Blue Gene is an IBM supercomputing project dedicated to building a new family of supercomputers optimized for bandwidth, scalability and the ability to handle large amounts of data while consuming a fraction of the power and floor space required by today's fastest systems. The full Blue Gene/L machine is being built for the Lawrence Livermore National Laboratory in California, and will have a peak speed of 360 teraflops. When completed in 2005, IBM expects Blue Gene/L to lead the Top500 supercomputer list. A second Blue Gene/L machine is planned for ASTRON, a leading astronomy organization in the Netherlands. IBM and its partners are currently exploring a growing list of applications including hydrodynamics, quantum chemistry, molecular dynamics, climate modeling and financial modeling.
About IBM
IBM is the world's largest information technology company, with 80 years of leadership in helping businesses innovate. Drawing on resources from across IBM and key Business Partners, IBM offers a wide range of services, solutions and technologies that enable customers, large and small, to take full advantage of the new era of e-business. For more information about IBM, visit www.ibm.com.
Photos of Blue Gene/L available at:
http://domino.research.ibm.com/Comm/bios.nsf/pages/bluegene-2004. html(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. You may also need to remove an extra space in the URL if one exists.)
Some more of IBM research - The work of the Bioinformatics & Pattern Discovery Group focuses on a number of theoretical and applied problems that are of relevance to computational molecular biology. During the last several years we have been working on the the following:
pattern and association discovery in event streams;
multiple sequence alignment;
new approaches for similarity searching in
protein/dna databases;
the analysis of gene expression data
the parallelization of our algorithms on both
shared-memory and message-passing architectures
establishing lower bounds on the number of irredundant
motifs contained in a given database as well as algorithms
for finding these motifs
the automated annotation of proteins directly from sequence;
the discovery of genes in prokarytotic genomes using
dictionary-driven approaches
the characterization and prediction of local
3D structure directly from sequence;
the discovery of tandem repeats in DNA sequences;
the automated classification of protein sets into families;
the automatic generation of composite descriptors
for arbitrary collections of biological sequences;
new techniques for principal component analysis with
application to rational drug design, gene expression
analysis, and other problems;
the determination of archaea-, bacteria- and eukaryota-
specific signatures,
comparative genomics
and other.
We have also compiled the Bio-Dictionary(TM) an exhaustive collection of 1-dimensional patterns (which we refer to as seqlets - for 'small sequences') by processing the GenPept and SwissProt & TrEMBL databases with Teiresias. This collection allows us to fully characterize the sequence space of natural proteins - to the extent allowed by the sampling provided by the sequences in the processed databases. We have shown that the seqlets the Bio-Dictionary(TM) contains capture conserved functional and structural signatures both within and across family boundaries.
We continuously produce metadata (i.e. 'content') from public databases of biological sequences. Recently, we began making available annotations of complete genomes
Mayo Clinic to Use IBM's Blue Gene
By Clint Boulton
August 5, 2004
Sinking its teeth deeper into the health care industry, IBM (Quote, Chart) this week agreed to let Mayo Clinic use its Blue Gene supercomputer to research diseases.
The goal is to tap into the abundance of new data to foster medical breakthroughs, according to a statement. Financial terms of the pact were not made public, but IBM and the Mayo Clinic said they would spend "millions of dollars per year in manpower, research and technology."
The Mayo Clinic will be the first medical institution to use the power of Blue Gene, accessing specialized algorithms to perform molecular modeling. IBM and the clinic will also aim to map current and historical patient records and link them to new types of medical information.
"Our collaboration with IBM is focused on advancing the Mayo Clinic mission in the areas of patient care and research," said Denis Cortese, M.D., president and CEO of Mayo Clinic. "We are at a point with standards in technology and new genomic-based analytic techniques where we can achieve more in the next 10 years than we've achieved in the last 100, and we see in IBM a partner with a very unique capacity to deliver expertise and innovation."
IBM and Mayo Clinic have already integrated 4.4 million patient records into a unified system, making it easier for physicians and researchers to call up info.
Going forward, both Big Blue and Mayo will integrate genomic and proteomic data with clinical records and public databases for use by physicians. The companies will also use Blue Gene to compare patient data to the data of other patients with similar disease characteristics.
For example, a doctor might be able to pinpoint the exact location of a patient's cancer, as well as its gene characteristics, and make a prognostication based on the outcomes of therapy in the last 500 patients with similar cancer.
The multi-billion-dollar medical field is a lucrative one for IBM and other high-tech companies, which are all jockeying for position in the world's largest life sciences companies.
IBM has locked down the Mayo Clinic since 2001 and Blue Gene, one of the company's most popular supercomputers, has been used by several government organizations for research. Last November, IBM introduced a smaller version of Blue Gene.
IBM wins on demand contract for Blue Gene
Updated: 5:57 p.m. ET Aug. 4, 2004
NEW YORK - International Business Machines Corp. <IBM.N> on Wednesday said that the Mayo Clinic will become its first on demand client to use the Blue Gene super computer.
Mayo Clinic is a not-for-profit organization based in Rochester, Minnesota, with medical and research facilities. It will use Blue Gene for simulations to find causes and cures for diseases.
Bill Zeitler, senior vice president of Systems and Technology group at IBM, said the application of super computing technology is going to lead to radical breakthroughs in medical science.
On demand computing is the marketing term IBM uses to describe a way for its customers to buy computers and related services as they need it, instead of purchasing expensive and powerful computers up-front that they may or may not fully use.
The concept is somewhat similar to time sharing of a vacation home or an executive jet.
Armonk, New York-based IBM, the world's largest computer services company, has been looking at ways to boost its slow growth in revenue and profits. On demand computing is one of its focus areas.
"This could be a very large market in terms of the services and hardware opportunity," said Zeitler.
IBM currently has two super computer centers dedicated to on demand computing. The two centers put together have a capacity of 17 teraflops, or 17 trillion mathematical operations per second.
Zeitler said that over the next two years, IBM's on demand super computing capacity could grow a 100 times to some 1,700 teraflops.
© Reuters 2004. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
IBM, Mayo extend partnership to find 'Holy Grail' of health care
They hope to tailor treatment based on data mining and genome research
Related to this topic
> Sidebar: Advocates say electronic records boost data privacy
> HHS Sets Plan for Adoption of Electronic Medical Records
> Widespread use of electronic health records to require broadband
> HHS pushes electronic health records
> Oracle retools E-Business Suite, business intelligence offerings
> Oracle tweaks app server, eyes new acquisitions
> UNC reaps savings from unified pharmacy system
> Securing business intelligence
Other resources
> Computerworld Executive Bulletin - IP Communications - Get this $49.95 value free for a limited time
News Story by Bob Brewin
AUGUST 05, 2004 (COMPUTERWORLD) - IBM and the Mayo Clinic yesterday announced the extension of a 3-year-old partnership designed to improve health care by correlating data from patient records to what Dr. Nina Schwenk, who heads Mayo's IT operations, calls "the Holy Grail [of medicine], individualized patient treatment" (see story).
Dr. Denis Cortese, president and CEO of the Mayo Clinic, predicted that the partnership could rapidly advance health care. "We are at a point with standards in technology and new genomic-based analytic techniques where we can achieve more in the next 10 years than we've achieved in the last 100, and we see in IBM a partner with a very unique capacity to deliver expertise and innovation," Cortese said in a statement.
IBM and the Mayo Foundation for Medical Education and Research, the formal name for the Rochester, Minn-based nonprofit health care organization, which operates clinics in Rochester, Jacksonville, Fla., and Scottsdale, Ariz., have spent the past two years mining data from the records of 4.4 million Mayo patients.
Now, the partnership wants to mine patient information in new ways and compare it with data from other patients with similar disease characteristics and genomic makeup, said Schwenk, who also serves on the board of governors of the Mayo Foundation. The partnership also plans to use the data to fine-tune treatment.
"Wouldn't it be marvelous if a doctor knew not just the exact location of the patient's cancer but its gene characteristics and the outcomes of therapy in the last 500 patients with cancer in that identical location and with those identical genetic characteristics?" Dr. Hugh Smith, vice president of the Mayo Clinic, said in a statement.
Individualized care could one day replace today's protocol-driven treatments, Schwenk said. Instead of treating cancer patients using a toxic stew of chemotherapy -- which can have debilitating side effects -- drugs could be tailored to a patient's genetic make up and particular cancer. Mayo and IBM will base treatments on information from the patient as well as on continuing genomic research, Schwenk said.
Data mining should allow Mayo doctors to zero in on successful treatments by harvesting information on related cases and the therapies and drugs that produced the best results, Schwenk said.
IBM intends to use its Blue Gene supercomputer on the project to advance its work in molecular modeling for disease research, said Drew Flaada, IBM 's director of the Mayo/IBM partnership. He said Mayo researchers would use Blue Gene to do "deep computing and deep science," including mathematical modeling and a simulation of gene structures to help predict disease behavior.
The partnership uses IBM pSeries servers based on the RISC PowerPC chip running the AIX operating system and an IBM DB2 database. The Blue Gene supercomputer, which is located at an IBM facility in Rochester near Mayo's headquarters, has a theoretical computing capacity of 360 TFLOPS and currently ranks as the fourth most powerful supercomputer in the world, IBM said.
Schwenk declined to specify the funding for the Mayo/IBM partnership, but said it is "significant -- a lot of zeros on both sides," and said IBM plans to do research to develop systems, products and tools for the health care industry.
WORKTOPLAY I;ll say it. ITS SO !!! $$$$ LOL
Biometrics Council on Terrorism meeting - attended by Tony Frudakis:
http://www.findbiometrics.com/Pages/news_releases/news451.html
Tom Colatosti, Chairman of BIO-key International and CEO of American Security Ventures Appointed to Advisory Board of Biometrics Council - May 22, 2003
Two recent college graduates, David J. Harris and Wm. Matthew Jaunich, have founded Biometrics Council, a non-profit organization dedicated to fostering public awareness of the potential of biometrics to substantially reduce the risk of terrorism to the United States. Mr. Harris graduated from Yale College in 2000, where he worked for former President Bush's brother, Jonathan, at his investment firm, J. Bush and Company, Inc. In addition, Mr. Harris co-authored the first study of women in cardiac trials funded by the National Institutes of Health in the New England Journal of Medicine. Mr. Jaunich, an honors graduate of the University of Southern California, is President of the Lucror Group, L.L.C., a private equity vehicle and consults for Fremont Partners, L.P., a merchant bank in San Francisco. Mr. Jaunich has also worked for Creative Artists Agency in Hollywood.
Within a few weeks, Mr. Harris and Mr. Jaunich have recruited luminaries of the intelligence community, academe and industry to the Board of Directors:
Arnaud de Borchgrave, Editor at Large, Washington Times; UPI, and Director, Transnational Threats, Center for Strategic and International Studies, Member, Secretary Ridge's Advisory Committee for Homeland Security
Margaret L. Johnson, Senior Lecturer, Department of Computer Science, Department of Symbolic Systems, Stanford University
Catherine Lotrionte, Adjunct Professor of Security Studies, Georgetown University. Professor Lotrionte's particular areas of expertise are national security law, international law and international security.
Carlos L. Signoret, Managing Director, Hispania Capital Partners.
In addition to the Board of Directors, Biometrics Council has an Advisory Committee of leaders from the industry, who offer insight but have no governance power.
The advisors are:
Alexander and Michael Bronstein, Members of the 3DFACE Research Group, Technion -- Israel Institute of Technology, twenty-two year old identical twins who developed a facial recognition algorithm that distinguishes between them, which was featured on CNN.
Thomas J. Colatosti, Chairman of the Board, BIO-key International (OTC Bulletin Board: BKYI) and Founder and Chief Executive Officer of American Security Ventures.
R. Terren "Terry" Dunlap, Chief Executive Officer of Ultra-Scan Corporation
Tony Frudakis, Founder, Chief Executive Officer and President of DNAPrint Genomics
Barry Hodge, President of AcSys Biometrics Corporation
Oliver "Buck" Revell, Chairman of the Board of Imagis Technologies, Inc. and retired Associate Deputy Director of the Federal Bureau of Investigation (FBI).
Biometrics Council is market-neutral and all directors have pledged not to own biometrics securities or accept profit incentives from the industry. This underscores their commitment to the proposition that biometrics in its various modalities, including facial-recognition, fingerprint, DNA, retinal and iris, palm and vein, could in a variety of applications enhance the safety of the American people.
Mr. Harris explained the Council's motivation: "Overwhelming evidence demonstrates that the use of weapons of mass destruction against the United States is imminent.
Warren Buffett, for instance, has declared that a nuclear attack on America is 'virtually a certainty.' If we are to preserve the American way of life, we must have a revolution in infrastructure. We believe a vital piece of this is biometrics."
Arnaud de Borchgrave stated, "The next generation will see electronics worn, ingested or implanted. Biometrics is an integral part of our national security as disruptive technologies keep America at the cutting edge of revolutionary change."
"After September 11, there was a surge in interest concerning identity technology, but this crest has fallen, and we are in an almost tranquil abeyance, a denial of the immediacy of the threat," Harris added.
Mr. Harris stresses this is not a partisan issue. "Secretary Rumsfeld has admonished that a weapons of mass destruction attack on America is not a matter of 'if', but 'when.'
Congressman Edward Markey, a Massachusetts Democrat, has been sounding the clarion call that we cannot continue status quo operation of nuclear power plants, given that they are capable of being weaponized. We want to seek out more people who do not view the threat of weapons of mass destruction through rose-colored glasses."
The Council has had discussions with various officials in the government, both active and retired, and is heartened by the interest in its initiatives. Lt. General Claudia Kennedy, former Deputy Chief of Staff of the Army for Intelligence, the first and only woman to achieve that rank in the United States Army, attended the Council's first meeting this winter.
SOURCE: Biometrics Council
Try this - ABC 15 NEWS STORY ON DNAPRINT
FULL VIDEO STORY.
ABC 15's Kaley O'Kelley introduces you to a geneology test that traces your roots to the year 48,000 B.C. Click the related link below for more info on the DNA Print.
http://www.abc15.com/video/misc/player-vnle.asp?pad=y&vid=http://real.scripps.com:8480/ramgen/ph...
Gcbr, thanks i'll try to fix
ABC 15 NEWS STORY ON DNAPRINT great Post money
FULL VIDEO STORY.
ABC 15's Kaley O'Kelley introduces you to a geneology test that traces your roots to the year 48,000 B.C. Click the related link below for more info on the DNA Print.
http://www.abc15.com/video/misc/player-vnle.asp?pad=y&vid=http://real.scripps.com:8480/ramgen/ph....
WGCU interview with Tony Frudakis from 19th July 2004
http://www.wgcu.org/listen/gulfcoast_live.asp
Some highlights:
They are not developing drugs yet but intend to.
The error rate of DNAWitness is 4-8% for any percentage measured.
They will use facial recognition software in conjunction with DNA Witness to construct digital sketches of suspects. Future traits to be covered by DNA Witness:
- Skin color
- Eye color
- Hair color
- Height
- Weight
- Nose shape
- Distance between eyes
- Distance between cheekbones
- Whether earlobes attached
- Longitude and latitude of face
- Depth of cranium
- Any unusual inherited traits e.g. skull shape
The interviewer referred to a paper that Tony has apparently written called "Pharmacogenomics: The Paradigm Shift". Not sure if, when, or in what journal this is to be published.
When asked about cardiac drug related classifier development, Tony mentioned that DNAP had concentrated on a number of types of drugs, and specifically mentioned ace inhibitors and statins.
When asked about ovarian cancer/chemotherapy confirmed that can predict taxol and carboplatin response (based on two genes) and said that they are in the later stages of validating ovanome and "discussing with various types of organizations mechanisms of getting this type of test used and accepted for compensation by insurance companies, etc."
Have a nice day all.
Johnathan Lancaster, M.D. is Moffitt's newly appointed Medical Director for the Lifetime Cancer Screening and Prevention Center at Moffitt Cancer Research Center.
Dr. Johnathan Lancaster is the Principal Investigator with Moffitt working with DNAPrint Genomics and Taxanes
Moffit Cancer Research Center - Lifetime Focuses on High-Risk Populations - Summer 2004
The Lifetime Cancer Screening & Prevention Center at Moffitt Cancer Center is heading in new directions – with a new medical director at its helm. Johnathan Lancaster, M.D., has been named medical director for Lifetime Cancer Screening & Prevention Center at Moffitt Cancer Center. He also is a member of the Gynecologic Oncology Program and the Experimental Therapeutics and Risk Assessment, Detection & Intervention Programs.
Dr. Lancaster will lead the directional change that Lifetime is making to focus more on high-risk populations. “We are turning Lifetime into a cancer screening research laboratory,” says Dr. Lancaster. “We are conducting studies that will enhance the art and the science of cancer screening such that we develop more sophisticated, successful, sensitive screening technologies.”
Additionally, Dr. Lancaster is leading the new Familial Breast and Ovarian Cancer Screening and Prevention Clinic at Lifetime. Clinics at Lifetime are concentrating on screening individuals at elevated risk for breast, ovarian, cervical and colon cancers. Clinics serving patients at high risk for skin and genitourinary cancers are planned, in addition to a clinic focused on individuals at increased risk for cancer based on the most common risk factor – age.
Care for individuals at highest risk will be overseen by an interdisciplinary medical team providing comprehensive, coordinated management in a single location. Prospective patients may be referred by their own physicians for genetics testing or can be evaluated individually through a screening process designed to determine predisposition to cancer. The patient may then be managed by the clinic or return to his or her own doctor. In the Familial Breast and Ovarian Cancer Screening and Prevention Clinic, patients at high risk for breast and ovarian cancers are overseen by Dr. Lancaster and Rebecca Sutphen, M.D., director of the Family Cancer Genetics Clinic. Genetic testing is available for mutations in BRCA1/ BRCA2, two genes associated with breast and ovarian cancer, as well as for genes or markers associated with colon cancer.
Patients are seen by genetic counselors, behavioral and psychosocial specialists familiar with high-risk gene carriers, and a nutritionist who conducts a risk assessment analysis and develops and evaluates dietary interventions that may impact risk.
Since family history is a strong indicator to developing breast and ovarian cancer, Dr. Lancaster envisions families attending the clinic – centralizing care for all family members at risk of developing cancer.
Drs. Lancaster and Sutphen also plan to conduct more clinical trials and to develop better screening strategies through their research. They also will co-direct the newly established genetics research laboratory at Lifetime. This laboratory will utilize state-of-the-art technology to examine subtle differences in DNA that may determine such things as whether an individual has a higher risk to develop cancer, may tend to develop cancer at a younger age, or may respond differently to chemotherapy or radiation treatment if cancer develops.
“I see no benefit to simply providing the same services as screening centers across America,” says Dr. Lancaster. “The role of Lifetime is to apply research strategies to develop the science of early detection such that we improve the way we screen patients.”
Clinical Trials Use Microarray Analysis
Dr. Lancaster served as medical director of the Cervix Clinic at Duke University Medical Center before joining Moffitt Cancer Center. While at Duke University, he and his colleagues applied microarray technology to better understand the gene profiles that underlie ovarian cancers. They identified gene expression profiles that differentiate cancers from long- and short-term survivors, patients that would and would not be amenable to optimal surgical debulking and, most interestingly, which cancers responded to specific chemotherapies and which ones did not. Preliminary data from those studies suggest they can accurately predict in 90% of the cases which tumors would respond to specific chemotherapies based on their gene expression profiles.
He currently is developing a translational trial in which he will use microarray analysis to design tailored therapies for individual patients with ovarian cancer. Designer chemotherapy will hopefully increase patient response rates and decrease the number of ineffective agents that the patient receives. “Such individualized treatments decrease unnecessary toxicities, allow patients to receive the most effective anticancer agents more quickly, and preserve bone marrow,” says Dr. Lancaster. “This approach may increase lifespan and, more importantly, should improve patient quality of life.”
Dr. Lancaster’s clinical research interests include the GOG-182, a national multicenter, five-arm, open-trial study, involving the Gynecological Oncology Group, a national and international collaboration of gynecological oncologists. The study evaluates the role of chemotherapeutics traditionally used in recurrent ovarian cancer. The first arm compares surgery followed by carboplatin and taxol to the four other arms, which include surgery, carboplatin, taxol and a salvage agent.
Quick Summary – Dr. Johnathan Lancaster, MD. – Principal Investigator for Moffit on Taxanes Projects with DNAPrint Genomics
* Promotion to Medical Director for Lifetime Cancer Screening & Prevention Center at Moffitt Cancer Center
* Leads the new Familial Breast and Ovarian Cancer Screening and Prevention Clinic at Lifetime
* Ongoing and new research on Carboplatin and Taxol
* Develops and uses MicroArrays for cancer diagnostics and screening
* Works with DNAPrint Genomics as Moffitt's principal investigator with Taxanes
** It appears DNAP is in very good company with Dr. Lancaster now the new Medical Director at Moffitt's Lifetime Cancer Center, working on clinical studies with excellent opportunities for Moffitt and DNAP to develop leading edge cancer screening methods and diagnostic microarrays...
Hauser CRO is a leader in production of research grade taxanes* and related compounds. These materials are available for purchase in milligram to gram quantities, and come with a certificate of analysis indicating chemical purity and identity.
Our technical staff can provide qualitative mixed standards for taxanes, including support in client projects involving our standards, and custom isolation or synthesis of taxanes.
*These compounds are not for human use.
Taxanes:
Paclitaxel
Baccatin-III
Cephalomannine (Paclitaxel related compound A)
10-Deacetylbaccatin-III
10-Deacetyltaxol
10-Deacetyl-7-epi-taxol (Paclitaxel related compound B)
10-Deaceyl-7-xylosyltaxol
7-epi-taxol
Taxol C
Taxol side chain alcohol
Taxol side chain methyl ester
7-xylosyltaxol
7-xylosyltaxol C
13-taxane HPLC mixture
Taxinine M
13-Acetyl-9-dihydrobacaatin III
Other Standards from Natural Sources:
artemisinin
carnosic acid
rosmarinic acid
epigallocatechin gallate (EGCG)
epicatechin gallate (ECG)
epicatechin (EC)
green tea polyphenols
black tea polyphenols
vidarabine
2,4,-hexadinenoic acid isobutyl amide
ABC 15 NEWS STORY ON DNAPRINT great Post money
FULL VIDEO STORY.
ABC 15's Kaley O'Kelley introduces you to a geneology test that traces your roots to the year 48,000 B.C. Click the related link below for more info on the DNA Print.
http://www.abc15.com/video/misc/player-vnle.asp?pad=y&vid=http://real.scripps.com:8480/ramgen/ph....
something to poke around in IBM Research - http://www.research.ibm.com/visualanalysis/biology.html#Anchor-Prototyp-43805
It looks like more and more that Technion in Haifa Israel os playing a Big roll with Dnap.
1} we have the Bronstein Twins {3-D Face scanner} who are members of the Biometrics Council that Tony is on.Their at the Technion Institute. Area involved w/ Dnap is Forensics.IMO
2}We have Dr. Ron Kimmel who works with the Bronstein Twins as top dog.But who also is a professor at Stanford university where we have another member of the Biometrics Council working in the SAME DEPT. as Dr. Kimmel a Margaret L. Johnson, Senior Lecturer, Department of Computer Science, Department of Symbolic Systems, Stanford University . Area involved with Dnap Computer and Forensics.IMO
3}Now we have Dr. D.M. Behar and Dr.D.Rosengarten and Dr. K.Skorecki and Dr. Bruce Rappaport working at Rambam Medical in Haifa,Israel. area of involved ancestry by DNA AND MEDICINE.and this is a Fact.
Ice105,ok i was not sure of the Month. Thanks
Thats it for now my chrilden are calling.
ok your not going to believe this - Guess who Dr.Doron M. Behar is.Do you know ? And Dr.Garrigan they are helping Dnap in their Ancestry work BUT they are very involved in Medicine as well.Dnap uses their work as reference material and most likely in other wats. Now Get this. Guess where they work ? Hit - 3-D Face Scanner !!!! Still dont know - Hint - Bronstein Twins;Dr.Kimmel Ok thats right at Technion in Haifa Israel.Take a look on right first par. down.
************************************************************************************************************
http://www.familytreedna.com/pdf/Behar_contrasting.pdf
eb0783, Thankyou for that post.I have talked to Dr.Moskowitz as well and found him to be a very nice guy.I hope he makes it with Gmed.I dont know how but i would like to see the FDA give him some kind of support.
From the interview. - When asked about ovarian cancer/chemotherapy confirmed that can predict taxol and carboplatin response (based on two genes) and said that they are in the later stages of validating ovanome and "discussing with various types of organizations mechanisms of getting this type of test used and accepted for compensation by insurance companies, etc."
DorseyE, Yes i thought it was from the WGCU interview with Tony Frudakis from 19th July 2004 But it could have mention somewhere else as well.
eb0783, Thank you for sharing this. I had no idea it is this Big.
Do you remember last July's stockholder's meeting ? Do you remember this ?
*************************************************************************************************
Ancestry 3.0 would take about a year to develop, but will require between $750K to $1 million to fund the research. DNAP would like to solicit a partner willing to fund it's development in exchange for a share of downstream revenues.
- Ovanome is about a year from market, and DNAP anticipates marketing through a partner. I asked if Statnome was similarly a year out, and the response surprised me. Tony indicated that Statnome would be marketed sooner and the marketing would be handled by DNAP. Obviously, the company is anticipating a much larger market for the Statin classifers which would make it cost effective to run the samples on the UHT.
************************************************************************************************
I really have to share this because i think there's something odd about the fact that there is so little info. out on Statnome that i cant help wonder if Tony is going to pull a BIG Surprise on everyone with News on either Statnome coming out or Ovanome this year. Tony has said Statnome is really top secret and a very big money maker.And then in the EXECUTIVE SUMMARY OF OVANOME we have this -
***************************************************************************************************
The clinical trial for OVANOME will be finished in early 2004. An application for approval to market, if required, will be submitted to the FDA by mid-2004 and approval obtained by early 2005. DNAP has a patent pending for compositions and methods relating to OVANOME. Sales of the OVANOME products to labs in 2005 will result in income of $4 million. This product launch will create a new, emerging US market of over $16 million. OVANOME is forecast to reach a peak-year sales record of $12 million in year three and hold steady for several years as the classifier test of choice in this market niche.
*******************************************************************************************
I guess i would like to believe that Tony is going to pull a Big surprise on us all this year.To much to wish for i guess.Dont mine me i'm just dreaming.
God Bless
Dnap's Statnome info. -
From 10Ksb 4-15-2003
Statnome. Statnome is the product we are developing in conjunction with a group of Jacksonville physicians to classify patients as adverse responders or good responders to a class of drugs called statins. Hypercholesterolemic and dyslipidemic patients are at increased risk for heart disease. Currently, these patients are prescribed medications, nicknamed "statins," to reduce this risk.Statins function to decrease cholesterol levels by inhibiting a key enzyme in the cholesterol pathway. According to the National Heart, Lung, and Blood Institute's National Cholesterol Education Program,
high cholesterol is one of the key risk factors for heart disease.
Heart disease is the leading cause of death for both men and women in the United States, and more than 90 million American adults, or about 50 percent of the population, have elevated blood cholesterol levels.
A study published in the New England Journal of Medicine in September 1998 says heart disease deaths have declined steadily over the last 30 years, decreasing by 10.3 percent between 1990 and 1994 alone. This
improvement is largely attributable to better prevention of heart disease through the widespread use of statins.
Notwithstanding the efficacy of this class of drugs, individual patients respond differently to statins. About 2-5% of patients are discontinued from statin treatment due to adverse experiences including hepatocellular toxicity (indicated by elevated serum levels of certain liver enzymes), and more rarely, acute renal failure. In
fact, it is recommended that physicians monitor this toxicity by performing liver function tests prior to, and at 12 weeks following,both the initiation of therapy and any elevation of dose, and periodically thereafter. As a recent Time magazine article points out,statins may potentially serve as a useful preventative tool to reduce
the risk of heart disease in the general, healthy population. A key impediment for the expansion of the statin market in this way is the danger posed by adverse events associated with use of these drugs. For example, the long-term effects of hepatocellular injury are not
clearly understood.
The Statnome product(s) could help reduce the risk associated with the use of statins in the general population. The Company expects its Statin project to result in several "diagnomics" test solutions for
routine patient pre-screening prior to statin prescription. Based on the prevalence of dyslipidemia and hypercholesteremia in the population, such a product could enjoy entry into a market in excess of several billion dollars (drug sales). At present our scientists have completed the screen of the xenobiotic genome for the Statnome project and are validating the performance of the resulting classifier.
***************************************************************************************
10k;
At present our scientists have completed the screen of the xenobiotic genome for the Statnome project and are validating the performance of the resulting classifier.
...and this:
Thus, the Company has scaled back its sample collection efforts and is focusing on validating its Statin prediction product (STATNOME) and building a market for and completing its DNA Witness 2.0 line of forensic products. Pending the acquisition of investment funding or the realization of profits from product sales, DNAPrint intends to resume previous rates of collection for its various developmental stage pharmacogenomics projects.
*************************************************************************************************
From the first Newsletter:
OTHER TESTS - We have finished both the genotyping and the computational screening for Lipitor and Zocor, and we have finished the genotyping but not the computational screening for about 15 other drugs we have good sample sizes for. As we complete these projects, we will disclose the results within a formal, peer-reviewed setting such as a professional meeting or in the scientific literature.
*************************************************************************************************
Sept. 23, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP - News) announced on Friday successful results from its ongoing research into the genetic basis for variable Statin response. The results were presented to an audience of health care professionals at the 7th Annual Disease Management Congress in Chicago, IL.
CEO Dr. Tony Frudakis described Company research that has resulted in the identification of certain gene variants associated with and predictive for Statin response. Statins are a class of drugs used to treat lipid disorders and reduce the risk of cardiovascular disease. Largely due to patient genetics, about 25% of patients fail to respond positively to any given Statin, but those that fail to respond to one often respond to another. The findings are the result of a two-year study that focused on 575 patients and seven different clinical measures of response. Using proprietary screening methods, Company scientists were able to identify an unexpectedly large number of variants linked to response. Those associated with response to standard doses of Artorvastatin (sold under the trade name Lipitor by Pfizer, NYSE:PFE) were generally different from those associated with response to standard doses of Simvistatin (sold under the trade name Zocor by Merck, NYSE:MRK), and those predictive for efficacy (how well the drug does its job) were different from those predictive of adverse events such as early stage hepatocellular toxicity (liver stress) or myalgia (muscle pain). The research condensed mathematical encodings for these variants, which the Company calls "eigengenotypes", into a complex genetics classifier capable of explaining almost all of the observed variability in response. Details on how the "eigengenotypes" were measured and computed, or from what genes they are derived were not presented.
The results were described as the fabric for a new genomics test, called STATNOME(TM), which the Company intends to market to the managed health care industry. By allowing physicians to match patients with the Statin most appropriate for their genetic constitution, STATNOME(TM) could enable a dramatic enhancement the therapeutic benefit of this class of drugs. The Company hopes that STATNOME(TM) will reduce the need for frequent follow up visits to the doctors office, obviate an entire menu of clinical tests for monitoring Statin response and reduce the waste that comes from giving medicines to people who are genetically incapable of responding to them. In so doing, the new test could help managed care providers save thousands of dollars per patient, while at the same time, treat their patients more effectively.
Until the tests are manufactured and distributed, Dr. Frudakis explained that the Company plans to exclusively provide STATNOME(TM) classification services for early clinical adopters and progressive patients. The commencement of this service would be announced at a later date. He also outlined Company plans to begin offering services based on the OVANOME(TM) test, which was introduced by the Company last year as the world's first genomics-based test for flagging patients who are incompatible with paclataxel and carboplatin combination chemotherapy (which is the current FDA approved first-line therapy for ovarian cancer; paclitaxel is sold under the trade name Taxol and carboplatin is sold under the trade name Paraplatin, both are manufactured by Bristol-Myers Squibb, NYSE:BMY). The commencement of STATNOME(TM) and OVANOME(TM) services would make DNAPrint the only laboratory in the world using internally-developed, wholly owned and drug-specific classifiers for the individualization of drug treatment. The tests would be among the very first genomics-based tests ever applied before routine drug use, or for any other clinical practice.
The STATNOME(TM) test could have significant implications for the safety and effectiveness of Artorvastatin and Simvistatin, which combine to serve a $12 billion annual market projected to grow to $20 billion by 2003. Though generally well tolerated, adverse events associated with the use of Statins have recently begun to receive widespread attention. Recently Bayer (NYSE:BAY - News) was forced to pull their Statin "Baycol" from the market due to a fatal response linked to muscle damage and myalgia. Though myalgia is reversible, like hepatocellular toxicity, it is part of a continuum of pathology that leads physicians to switch treatments. By flagging the genetically incompatible before treatment, the Company hopes that STATNOME(TM) will help minimize the negative impact of this widely used class of drugs and change the "trial and error" mentality of today's drug prescription process. In addition, STATNOME(TM) could help expand the market for Statins, many of which are already considered "blockbuster" drugs. For example, Statins are usually given to patients that have a lipid condition that can lead to cardiovascular disease, but there are an estimated 30 million healthy people in the US who are at risk of developing this condition for whom Statins would serve as an effective prophylactic. Mainly due to side effects, and the cost of monitoring these side effects, the cost/impact and risk/reward values for a healthy person at risk of developing a lipid disorder is less desirable than that for the already afflicted. As a result, Statins are still not used in the healthy population. By accurately flagging those who would develop an adverse reaction to them before the drug is given, STATNOME(TM) could someday help Statins overcome this barrier for more widespread use.
*************************************************************************************************Some of the Statinome drugs DNAP is reviewing...01-01-02
Baycol........>now banned by the FDA for high risks involved.
Lescol
Lipitor
Lopid
Mevacor
Niacin
Niaspan
Pravachol
Zocor
http://www.dnaprint.com/bioform.pdf
*************************************************************************************************
From the shareholders meeting March, 2003 -Reported by worktoplay - post# 232636
Ovanome is about a year from market, and DNAP anticipates marketing through a partner. I asked if Statnome was similarly a year out, and the response surprised me. Tony indicated that Statnome would be marketed sooner and the marketing would be handled by DNAP. Obviously, the company is anticipating a much larger market for the Statin classifers which would make it cost effective to run the samples on the UHT.
*************************************************************************************************